Blueprint
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): December 11,
2018
|
CORMEDIX
INC.
|
|
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
|
Delaware
|
001-34673
|
20-5894890
|
|
(State
or Other Jurisdictionof Incorporation)
|
(CommissionFile
Number)
|
(IRS
EmployerIdentification No.)
|
|
400 Connell Drive,
Suite 5000, Berkeley Heights, NJ
|
07922
|
|
Address of
Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code
(908)
517-9500
|
(Former
Name or Former Address, If Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07.
Submission
of Matters to a Vote of Security Holders.
The
Company’s 2018 annual meeting of stockholders was held on
December 11, 2018. At the meeting, stockholders elected the
following six members to the Company’s Board of Directors for
a term expiring at the annual meeting of stockholders in 2019,
based on the following votes:
|
Member
|
For
|
Withheld
|
Broker
Non-Votes
|
|
Khoso
Baluch
|
17,078,603
|
3,399,817
|
61,188,542
|
|
Janet
Dillione
|
18,911,474
|
1,566,946
|
61,188,542
|
|
Gary
Gelbfish
|
19,603,724
|
874,696
|
61,188,542
|
|
Myron
Kaplan
|
17,707,417
|
2,771,003
|
61,188,542
|
|
Mehmood
Khan
|
18,847,399
|
1,631,021
|
61,188,542
|
|
Steven
Lefkowitz
|
19,667,027
|
811,393
|
61,188,542
|
Also,
at the meeting, stockholders approved on a non-binding advisory
basis the Company’s executive compensation. The vote for such
approval was 17,269,019 shares for, 2,931,056 shares against,
278,345 shares abstaining and 61,188,542 broker
non-votes.
Finally, at the
meeting, stockholders also ratified the appointment of Friedman LLP
as the Company’s independent registered public accounting
firm for the fiscal year ending December 31, 2018. The vote for
such approval was 80,445,413 shares for, 862,828 shares against,
358,721 shares abstaining and no broker non-votes.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
CORMEDIX INC.
|
|
|
|
|
|
|
|
Date: December 11,
2018
|
By:
|
/s/ Robert W.
Cook
|
|
|
|
|
Name Robert W
Cook
|
|
|
|
|
Title
Chief Financial Officer
|
|